TOP

*Name

Phone

*Email

*Company/Institute

Consultation content

*Verification code

Contact Sales


Sales Image

Contact Sales Assistant


Sales Assistant Image

Contact PM


PM Image
Consult Now
Is your siRNA "silent" again? No, silence is useless! A must-read guide for researchers to avoid the pitfalls of oligonucleic acid testing!
2026-06-26
Is your siRNA "silent" again? No, silence is useless! A must-read guide for researchers to avoid the pitfalls of oligonucleic acid testing!
For small nucleic acid tools such as siRNA and shRNA, this guide covers best practices to avoid common pitfalls across the entire workflow – from sequence design and chemical modification to transfection experiments – including target selection, off‑target control, proper controls, and in vivo delivery strategies. GentleGen's one‑stop service platform deeply integrates core capabilities including target evaluation, sequence design, synthesis and purification, activity screening, and modification conjugation, delivering an "idea‑to‑reality" R&D experience for nucleic acid drug development.
View More
Opportunities and Challenges of AAV Gene Therapy, GentleGen: Full-chain technical support for AAV drug development!
2026-06-26
Opportunities and Challenges of AAV Gene Therapy, GentleGen: Full-chain technical support for AAV drug development!
GentleGen provides full‑chain technical support for AAV‑based gene therapy development, spanning from vector construction to regulatory filing for market approval. Its NGSafety® platform is specifically dedicated to quality control and safety assessment of AAV therapeutics, leveraging high‑throughput sequencing to analyze vector genome integrity, integration sites, residual impurities, and replication‑competent AAV (rcAAV) contamination.
View More
GentlePore nanopore sequencing enables DNA to "pass through tunnels" to read code—GentleGen's third-generation sequencing technology is here!
2026-06-26
GentlePore nanopore sequencing enables DNA to "pass through tunnels" to read code—GentleGen's third-generation sequencing technology is here!
GentleGen's GentlePore nanopore sequencing service enables direct sequencing without fluorescent labeling or PCR amplification, offering the advantages of speed, high accuracy, and low cost.
View More
In an era of strong regulation, GentleGen' biopharmaceutical safety evaluation collaborates to build a "safety moat" for innovative drugs.
2026-06-26
In an era of strong regulation, GentleGen' biopharmaceutical safety evaluation collaborates to build a "safety moat" for innovative drugs.
GentleGen's NGSafety™ one‑stop safety evaluation platform leverages next‑generation sequencing (NGS) technology to cover mRNA, CRISPR, AAV, and other modalities, delivering a "multi‑assay‑in‑one" capability. Designed to address increasingly stringent regulatory requirements, the platform facilitates IND filings for CGT (cell and gene therapy) products with both the NMPA (China) and the FDA (U.S.).
View More
From Design to Analysis: GentleGen's CRISPR gRNA Library Screening, One-Step Solution!
2026-06-25
From Design to Analysis: GentleGen's CRISPR gRNA Library Screening, One-Step Solution!
GentleGen's CRISPR gRNA library screening service addresses four critical challenges: low synthesis mutation rate, high sgRNA accuracy, excellent library coverage, and superior uniformity.
View More
How GentleGen leverages ASO to write a new chapter in precision therapy amid the oligonucleotide wave
2026-06-25
How GentleGen leverages ASO to write a new chapter in precision therapy amid the oligonucleotide wave
Against the backdrop of rapid global growth in the small nucleic acid therapeutics market, antisense oligonucleotide (ASO) technology has demonstrated core value in the field of precision medicine. The commercial landscape for small nucleic acid therapeutics experienced a significant surge in 2025–2026, highlighted by GSK's Bepirovirsen achieving milestone progress toward a "functional cure" for hepatitis B. The efficacy and safety of ASO drugs are highly dependent on sequence design and chemical modification strategies. Leveraging its intelligent design platform and flexible synthesis production lines, GentleGen empowers early‑stage R&D and process scale‑up for small nucleic acid therapeutics.
View More
From genes to antibodies with one-stop services, how does GentleGen's fully automated platform rewrite the rules of innovative drug R&D?
2026-06-25
From genes to antibodies with one-stop services, how does GentleGen's fully automated platform rewrite the rules of innovative drug R&D?
Accelerating antibody drug discovery and development remains an enduring priority in the biopharmaceutical industry. While traditional R&D workflows continue to grapple with lengthy lead times and prohibitive costs, GentleGen——a leading gene‑technology application platform——has leveraged its proprietary GentSynExp 3.0 G‑Lab fully automated platform to decisively break this deadlock.
View More
Global antibody drug industry trends: Emerging Leader in Automated Gene Services—GentleGen
2026-06-25
Global antibody drug industry trends: Emerging Leader in Automated Gene Services—GentleGen
The global antibody drug market is maintaining structural growth on a trillion‑dollar scale. In 2025, the global antibody market was valued at approximately $240 billion, and is projected to reach $460 billion by 2035, representing a compound annual growth rate (CAGR) of 6.7%. Growth drivers are rapidly shifting from traditional monoclonal antibodies to next‑generation modalities, with ADCs and bispecific antibodies emerging as the core engines. GentleGen is the first gene technology platform in China to achieve end‑to‑end automated scale‑up applications, powered by a core of "automation and intelligence," and offers one‑stop solutions covering gene synthesis, sequencing, editing, and expression.
View More
2026 Dual-Target siRNA Year Anniversary: Clinical Breakthroughs and Dual Validation of Billion-Yuan Transactions!
2026-06-25
2026 Dual-Target siRNA Year Anniversary: Clinical Breakthroughs and Dual Validation of Billion-Yuan Transactions!
Since the first siRNA drug was approved in 2018, small interfering RNA (siRNA) therapeutics have demonstrated clinical value in rare diseases, metabolic disorders, and other areas. However, in complex diseases driven by dysregulated multi‑gene networks – such as cancer and cardiovascular diseases – single‑target strategies often fall short. This has given rise to dual‑target siRNA technology, which is emerging as one of the most promising directions in RNA interference (RNAi) therapeutics. Since 2026, this field has witnessed intensive breakthroughs, transitioning from technical validation to clinical‑stage pipelines.
View More
GentleGen's G-Lab fully automated platform enables efficient delivery from gene synthesis to antibody expression within 7-10 days
2026-06-25
GentleGen's G-Lab fully automated platform enables efficient delivery from gene synthesis to antibody expression within 7-10 days
GentleGen leverages its self‑developed GentSynExp 3.0 G‑Lab, a fully automated gene and antibody platform, to build a one‑stop solution covering the entire workflow from gene design, synthesis, and validation to protein expression and antibody development. With its technological advantages in automation, high throughput, and high precision, the company provides the industry with efficient, stable, and cost‑effective R&D support.
View More
12
Pre-sales consulting

Pre-sales consulting

A more reliable solution for your needs.
Download

Download

Welcome to our product library.
Sales network

Sales network

Complete sales and service network to ensure product quality.
Event Promotions

Event Promotions

Add to cart now and enjoy this shopping extravaganza!